Outcome of Radiation Therapy in Urinary Bladder Squampus Cell Carcinoma
Outcome of Radical Radiation Therapy in Squampus Cell Carcinoma
1 other identifier
observational
40
0 countries
N/A
Brief Summary
Detection of distribution of clinico-pathological features of squamous cell carcinoma of urinary bladder and their relation to treatment outcome.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2022
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 23, 2021
CompletedFirst Posted
Study publicly available on registry
March 25, 2021
CompletedStudy Start
First participant enrolled
April 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2023
CompletedAugust 18, 2021
August 1, 2021
9 months
March 23, 2021
August 17, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Disease free survival
Disease free survival
baseline
Interventions
Radiotion therapy squamous cell carcinoma in cancer bladder
Eligibility Criteria
Patient with urinary bladder squamous cell carcinoma recieved radiotherapy .
You may qualify if:
- age 18-70 .
- histologically proved urinary bladder squamous cell carcinoma.
- non-metastatic disease.
- all patients who underwent radical treatment or bladder preserving approach.
- patient with isolated urinary bladder carcinoma (no other or previous primary).
You may not qualify if:
- age \< 18 , \> 70.
- patient not documented having bladder squamous cell carcinoma by biopsy (cystoscopic or operative).
- metastatic disease.
- patient with synchronous or metachronous double primary
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
1. Messing EM. Urothelial tumours of the bladder. In: Wein AJ, Kavoussi LR, Novick AC, Partn AW, Peters CA (editors). Campbell-Walsh Urology. 9th(3). Philadelphia: Saunders Elsevier 2007: pp.2407-2446. 2. Christopher Ho Chee Kong, Praveen Singam, Goh Eng Hong, Lee Boon Cheok, Muhammad Azrif, Azmi Mohd Tamil et.al (2010). Clinicopathological features of bladder tumours in a single insttuton in Malaysia. Asian Pasifc J cancer Prev. 2010; 11: 149-152. 3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009). Cancer statstcs. CA Cancer J Clin. 2009 ; 59: 529-533. 4.Zarzour AH , Selim M, Abd -Elsayed A et al., muscle invasive bladder cancer in uppr Egypt : the shift in risk factors and tumor characteristics, license Bio Med central BMC Cancer doi.:10.1186 / 1471-2407-8-250-,2008. 5.Amal S. Ibrahim, Nabiel N Mikhail et al . Egypt National Cancer Registry Damietta profile - 2009: publication number RR2 July, 2011. 6.M.Nabil El- Bolkiny , M.Akram Nouh , Tarek N.El-Bolkiny et al.topographic pathology of cancer , the national cancer institute, Cairo University , 2008. 7.Jason A.Efstathiou, Anthony L.Zietman, Jhon J. Coen, clinical Radiation Oncology , bladder cancer ;3rd edition : p1216-1241, 2012.
BACKGROUND
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
March 23, 2021
First Posted
March 25, 2021
Study Start
April 1, 2022
Primary Completion
January 1, 2023
Study Completion
April 1, 2023
Last Updated
August 18, 2021
Record last verified: 2021-08